Last updated: June 2026 · Reviewed June 2026 · Built by the InjectBuddy team
What is the semaglutide titration schedule? the week-by-week dose ladder
The standard semaglutide titration schedule steps the dose up every four weeks: for weight management (Wegovy) it runs 0.25 mg, then 0.5, 1, 1.7 and finally 2.4 mg once weekly; for type 2 diabetes (Ozempic) it runs 0.25, 0.5, 1 and up to 2 mg. Each step holds for at least four weeks so gut side effects settle before the dose climbs, and the 0.25 mg start is a tolerance ramp, not a treatment dose. This guide walks through the week-by-week dose ladder for both labels, explains the maths behind each draw, and answers the questions people ask most about titrating semaglutide.
Key takeaways
- Both Wegovy and Ozempic begin at 0.25 mg once weekly for 4 weeks, then escalate one step at a time.
- Wegovy tops out at 2.4 mg (16 weeks of titration); Ozempic tops out at 2 mg.
- Hold each step for at least 4 weeks; if a step is rough, the label allows delaying escalation rather than stopping.
- The mg is the dose; the syringe units are volume. Plan the calendar and the draw with the GLP-1 titration calculator.
The week-by-week ladder
Titration means raising the dose in fixed steps instead of starting at the target. Semaglutide is titrated because its gastrointestinal effects (nausea, fullness, occasional vomiting) are dose-related and ease with exposure. The Wegovy label sets a 16-week escalation before the 2.4 mg maintenance dose, and the Ozempic label uses the same four-weeks-per-step rhythm up to 2 mg. The numbers below are taken directly from those two FDA labels.
| Weeks | Wegovy (weight) | Ozempic (T2D) | Units at 1 mg/mL* |
|---|---|---|---|
| 1–4 | 0.25 mg | 0.25 mg | 25 units |
| 5–8 | 0.5 mg | 0.5 mg | 50 units |
| 9–12 | 1 mg | 1 mg | 100 units |
| 13–16 | 1.7 mg | 2 mg (max) | 170 / 200 units |
| 17+ | 2.4 mg (max) | — | 240 units |
*The units column assumes a reconstituted compounded vial at 1 mg/mL drawn on a U-100 insulin syringe, purely to show the scale. Branded pens dial the dose for you, so you never count units with a Wegovy or Ozempic pen. The maintenance dose is the last row each column reaches.
Why the four-week steps matter
The four-week hold is deliberate. In the STEP 1 trial of semaglutide 2.4 mg, participants reached the top dose only after a 16-week run-in, and the gradual climb is part of why the dose was tolerable enough to study at scale. The Wegovy label states plainly: follow the escalation to reduce the risk of gastrointestinal reactions, and if a patient cannot tolerate a step, consider delaying escalation by four weeks rather than discontinuing.
Two unit systems collide here, so keep them separate. The milligram is the dose the label prescribes; the syringe unit is a volume mark where 100 units equal 1 mL. They only line up once you know the concentration, which is why a 0.25 mg step can be 25 units in one vial and 13 units in another.
How this is calculated
For anyone using a reconstituted vial rather than a pen, the draw for each titration step is one division. Convert the prescribed dose and the vial concentration to the same mass unit, divide dose by concentration to get milliliters, then multiply by 100 for U-100 units:
units = (dose mg ÷ concentration mg/mL) × 100
The arithmetic never changes across the ladder — only the dose number does. That is the whole point of a titration calculator: it re-runs the same division for each week's target so you do not move a decimal place by hand. Every worked example below uses that one formula.
0.25 mg ÷ 1 mg/mL = 0.25 mL → 25 units. The opening step on a 1 mg/mL vial.
0.5 mg ÷ 1 mg/mL = 0.5 mL → 50 units. The dose doubles, so the draw doubles.
1 mg ÷ 1 mg/mL = 1.0 mL → 100 units — a full 1 mL U-100 syringe.
1.7 mg ÷ 1 mg/mL = 1.7 mL → 170 units, which needs two draws on a 1 mL syringe.
2.4 mg ÷ 1 mg/mL = 2.4 mL → 240 units at this dilution. See 2.4 mg units by concentration for stronger mixes.
0.25 mg ÷ 2 mg/mL = 0.125 mL → 12.5 units. Identical dose, half the units, because the vial is twice as strong.
2 mg ÷ 5 mg/mL = 0.4 mL → 40 units. A concentrated 5 mg/mL vial keeps even the top dose under half a milliliter.
0.25 mg = 250 mcg. Mixing mg and mcg is the classic 10× error — convert before you divide, every time.
Adjusting and tracking the schedule
If a step brings on rough nausea, the labelled option is to stay on the current dose for an extra four weeks before trying the next one — escalation is paused, not abandoned. Missing an injection has its own rules; see the missed GLP-1 dose guide for the label's window before you skip or double up. Whatever your plan, write the dates down: a titration that drifts loses the four-week structure that makes it tolerable.
To map your own calendar and, if you compound, the units for each step, use the GLP-1 titration calculator. For the wider rationale on why these medicines escalate at all, the semaglutide dosing guide and GLP-1 titration planner guide go deeper.
So, what is the semaglutide titration schedule?
The semaglutide titration schedule is a stepwise dose-escalation plan that runs for 16 weeks before the maintenance dose is reached. Both Wegovy and Ozempic begin at 0.25 mg once weekly for four weeks, then increase one step every four weeks — Wegovy tops out at 2.4 mg and Ozempic at 2 mg. The formula for each draw on a reconstituted vial is: units = (dose mg ÷ concentration mg/mL) × 100. To map out your own calendar and syringe units for every step, use the GLP-1 titration calculator.
FAQs
What is the semaglutide titration schedule?
How long does the full semaglutide titration take?
Can I skip a titration step if I feel fine?
What if I cannot tolerate the next dose?
How many units is 0.25 mg semaglutide on a 1 mg/mL vial?
Sources
- FDA / DailyMed. Wegovy (semaglutide) injection — Dosage and Administration, Table 1 escalation schedule. DailyMed Wegovy label.
- FDA / DailyMed. Ozempic (semaglutide) injection — Dosage and Administration, 0.25 to 2 mg escalation. DailyMed Ozempic label.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med 2021. STEP 1 trial on PubMed (PMID 33567185).
- CDC. Safe Injection Practices to Prevent Transmission of Infections to Patients. CDC injection safety guidance.
- FDA. Wegovy (semaglutide) Prescribing Information — original 2021 approval, Section 2 Dosage and Administration. FDA Wegovy prescribing information (PDF).
- Smith ZR, et al. Semaglutide. StatPearls. Treasure Island (FL): StatPearls Publishing. Semaglutide StatPearls chapter.
- Collins L, Costello RA. Glucagon-Like Peptide-1 Receptor Agonists. StatPearls. Treasure Island (FL): StatPearls Publishing. GLP-1 receptor agonists StatPearls chapter.
- Bergmann NC, et al. Once-Weekly Semaglutide for Weight Management: A Clinical Review. PMC. Once-weekly semaglutide clinical review on PMC.
- Singh G, et al. Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations. PMC. Clinical insight on semaglutide for weight management on PMC.
- Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med 2016. SUSTAIN-6 trial on PubMed (PMID 27633186).
- Aroda VR, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes Metab 2019. SUSTAIN 1-7 insights review on PubMed (PMID 30615985).
This guide is for general educational purposes only and does not constitute medical advice. Dose, schedule, and titration decisions belong to your prescriber. InjectBuddy performs volume and ratio maths only. Always follow your prescriber's specific instructions and the product label.